Piramal Pharma Limited (PPL) has announced a significant addition to its Board of Directors. The company's Board has approved the appointment of Mr. Amit Soni as a Non-Executive Independent Director, subject to shareholder approval. This strategic move aims to bring valuable expertise and perspective to PPL's leadership team.

Key Appointment Details

About Amit Soni

Mr. Soni brings over two decades of investment experience to Piramal Pharma. His impressive career highlights include:

• Current role as Partner at CVC Capital
• Established CVC's India business in 2017
• Led $980 million deployment across 5 deals at CVC Capital
• Previous 9-year tenure with General Atlantic
• Experience in technology, financial services, and healthcare sectors

Notable Achievements

Under Mr. Soni's leadership at CVC Capital, some remarkable investments include:

1. Creation of Gujarat Titans, a team in the Indian Premier League
2. Majority stake acquisition in Healthcare Global, a leading oncology chain in India

Educational Background

Mr. Soni's appointment is expected to bring fresh perspectives and valuable insights to Piramal Pharma Limited, potentially influencing the company's strategic decisions and growth trajectory in the coming years.

The company has confirmed that Mr. Soni is not related to any existing Directors of Piramal Pharma Limited and is not debarred from holding the office of Director by any regulatory authority.

This appointment aligns with PPL's commitment to maintaining a strong and diverse board, which is crucial for effective corporate governance and strategic guidance in the competitive pharmaceutical industry.

Piramal Pharma has achieved a significant regulatory milestone for its bioconjugates manufacturing facility in Grangemouth, UK. The facility has received updated Good Manufacturing Practice (GMP) certificates from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), reinforcing its compliance with current manufacturing standards.

Key Highlights

• Facility Location: Grangemouth, UK
• Regulatory Body: UK's Medicines and Healthcare products Regulatory Agency (MHRA)
• Certification: Updated Good Manufacturing Practice (GMP) certificates
• Significance: Ensures compliance with current manufacturing standards

Impact on Operations

The updated GMP certification is crucial for Piramal Pharma as it:

1. Supports the company's pharmaceutical operations
2. Ensures compliance with regulatory requirements
3. Validates the facility's adherence to high-quality manufacturing practices

This regulatory approval underscores Piramal Pharma's commitment to maintaining stringent quality standards in its bioconjugates manufacturing processes. The certification may potentially enhance the company's position in the pharmaceutical industry, particularly in the specialized field of bioconjugates.

For stakeholders and partners, this update provides assurance of Piramal Pharma's continued dedication to quality and regulatory compliance in its UK operations.